1000 SPRING ST, SILVER SPRING, MD
Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
Investor Presentation
Financial Results, Press Release
Announces Appointment of Kevin J. Tracey to its Board of Directors
Reports Record Third Quarter 2025 Financial Results
TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
Announces $1 Billion Accelerated Share Repurchase Program
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Correspondence
Amended Tender Offer Statement by Third Party